PA
VYGR icon

Parallel Advisors’s Voyager Therapeutics VYGR Stock Holding History

Parallel Advisors’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-163
Closed -$924 – 3683
2024
Q4 		$924 Buy
+163
New +$1.05K ﹤0.01% 3125
2023
Q4 		– Sell
-49
Closed -$380 – 3488
2023
Q3 		$380 Hold
49
– – ﹤0.01% 3154
2023
Q2 		$561 Hold
49
– – ﹤0.01% 3078
2023
Q1 		$378 Buy
+49
New +$390 ﹤0.01% 3187

Other funds holding VYGR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parallel Advisors's VYGR Position: Q1 2025 in Review

Parallel Advisors sold out of Voyager Therapeutics (VYGR) in Q1 2025, closing a stake of 163 shares — an estimated $924 sold.

Parallel Advisors first reported a position in VYGR in Q1 2023 and held it in 4 quarters. The position peaked at $924 in Q4 2024. 116 funds tracked by Wall St. Rank hold VYGR as of Q1 2025.

  • Parallel Advisors reported no remaining Voyager Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Parallel Advisors sold 163 Voyager Therapeutics shares in Q1 2025, an estimated $924.
  • Parallel Advisors first reported a position in Voyager Therapeutics in Q1 2023 and held it in 4 quarters.
  • Parallel Advisors's Voyager Therapeutics position peaked at $924 in Q4 2024.
  • 116 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2025.

Based on Parallel Advisors's 13F filing for Q1 2025, filed 8 Apr 2025.